Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by $^{11}$C-methionine PET co-registered with MRI

Olympia Koulouri¹, Narayanan Kandasamy¹, Andrew C Hoole², Daniel Gillett³, Sarah Heard³, Andrew S Powison¹, Dominic G O’Donovan⁴, Anand K Annamalai¹, Helen L Simpson¹, Scott A Akker¹⁰, Simon J B Aylwin¹¹, Antonia Brooke¹², Harit Buch¹³, Miles J Levy¹⁰, Niamh Martin¹⁵, Damian Morris¹⁶, Craig Parkinson¹⁶, James R Tysome⁵, Tom Santarius⁶, Neil Donnelly⁶, John Buscombe³, Istvan Boros⁹, Rob Smith⁹, Franklin Aigbirhio⁹, Nagui M Antoun⁷, Neil G Burnet⁸, Heok Cheow⁴, Richard J Mannion⁶, John D Pickard⁶, 9 and Mark Gurnell¹

¹Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, ²Department of Medical Physics, ³Department of Nuclear Medicine, ⁴Department of Pathology, ⁵Department of Otolaryngology, ⁶Department of Neurosurgery, ⁷Department of Oncology, ⁸Wolfson Brain Imaging Centre, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK, ⁹Department of Endocrinology, St Bartholomew’s Hospital, London, UK, ¹⁰Department of Endocrinology, King’s College Hospital, London, UK, ¹¹Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter Hospital, Exeter, UK, ¹²Department of Diabetes and Endocrinology, New Cross Hospital, Wolverhampton, UK, ¹³Department of Endocrinology, Leicester Royal Infirmary, Leicester, UK, ¹⁴Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK, and ¹⁵Diabetes and Endocrine Centre, Ipswich Hospital, Ipswich, UK

Abstract

Objective: To determine if functional imaging using $^{11}$C-methionine positron emission tomography co-registered with 3D gradient echo MRI (Met-PET/MRI), can identify sites of residual active tumour in treated acromegaly, and discriminate these from post-treatment change, to allow further targeted treatment.

Design/methods: Twenty-six patients with persistent acromegaly after previous treatment, in whom MRI appearances were considered indeterminate, were referred to our centre for further evaluation over a 4.5-year period. Met-PET/MRI was performed in each case, and findings were used to decide regarding adjunctive therapy. Four patients with clinical and biochemical remission after transsphenoidal surgery (TSS), but in whom residual tumour was suspected on post-operative MRI, were also studied.

Results: Met-PET/MRI demonstrated tracer uptake only within the normal gland in the four patients who had achieved complete remission after primary surgery. In contrast, in 26 patients with active acromegaly, Met-PET/MRI localised sites of abnormal tracer uptake in all but one case. Based on these findings, fourteen subjects underwent endoscopic TSS, leading to a marked improvement in (n=7), or complete resolution of (n=7), residual acromegaly. One patient received stereotactic radiosurgery and two patients with cavernous sinus invasion were treated with image-guided fractionated radiotherapy, with good disease control. Three subjects await further intervention. Five patients chose to receive adjunctive medical therapy. Only one patient developed additional pituitary deficits after Met-PET/MRI-guided TSS.

Conclusions: In patients with persistent acromegaly after primary therapy, Met-PET/MRI can help identify the site(s) of residual pituitary adenoma when MRI appearances are inconclusive and direct further targeted intervention (surgery or radiotherapy).
Introduction

Transsphenoidal surgery (TSS) remains the treatment of choice for functioning pituitary tumours causing acromegaly, Cushing’s disease and central hyperthyroidism (thyrotropinoma), and in patients with prolactinoma who are intolerant to medical therapy. However, even in the hands of experienced surgeons, persistent/recurrent disease requiring additional therapy (repeat surgery, radiotherapy (RT) or long-term medical treatment) is not uncommon, and in the case of acromegaly, additional therapy may be required in up to 50% of macroadenomas (1). Post-operative decision making in these patients is guided by several factors, including clinical and biochemical assessment of endocrine status and the identification of residual tumour on follow-up scanning. However, standard pituitary imaging (magnetic resonance imaging (MRI) or, less commonly, computerised tomography (CT)) does not always reliably distinguish between residual tumour, post-surgical change and normal pituitary tissue (2, 3). In this context, the likelihood that the patient will be offered further treatment with targeted therapies such as repeat TSS or stereotactic radiosurgery (SRS) is diminished. Although conventional fractionated RT is effective in controlling residual endocrine hyperfunction and preventing tumour growth, it carries an increased risk of hypopituitarism (4). In addition, potential links to second tumour growth (e.g. meningioma) and premature cerebrovascular disease have also been suggested (5), although recent studies have shown no additional excess beyond that observed in patients undergoing surgery alone (6, 7).

More reliable techniques for discriminating between residual functioning tumour, post-treatment change and the normal pituitary gland could therefore help identify those patients with persisting acromegaly who are most likely to benefit from repeat TSS or targeted RT. A role for functional imaging in the post-operative management of pituitary tumours has been proposed previously, but is not currently in routine clinical use (2, 3, 8, 9). 18F-fluorodeoxyglucose (FDG), the positron emission tomography (PET) tracer most commonly used in oncology, has been used successfully to locate microadenomas or residual tumour after surgery in some patients but, importantly, it lacks sensitivity, and its utility is also limited by high uptake into surrounding normal brain tissue (8, 9). In contrast, 11C-methionine exhibits a more favourable pituitary-to-brain uptake ratio, and several studies have demonstrated its ability to identify residual pituitary adenoma (2, 3, 9, 11). However, a key limitation in many of the early studies was the restricted anatomical resolution offered by PET or PET-CT. This presents a particular challenge when trying to accurately localise small (sub-centimetre) lesions, which may not be readily differentiated from uptake into adjacent normal pituitary tissue (12). The absence of readily available PET-MRI has prompted some workers to assess the utility of merging (co-registering) PET-CT and MRI images (from this point onward referred to as Met-PET/MRI) to provide enhanced anatomical definition at sites of 11C-methionine tracer uptake (9, 10). However, to date, little data correlating imaging findings with subsequent treatment decisions and clinical outcomes have been reported (9, 10).

Here, we report our findings in 30 consecutive patients with acromegaly referred to our service for further evaluation because of indeterminate post-treatment MRI appearances and describe how treatment decisions were informed by the findings on Met-PET/MRI.

Subjects and methods

Patients

Between June 2011 and December 2015, 30 patients (16 women, 14 men; mean age 48 yr (range 24–75 yr)) were referred to our university teaching hospital pituitary service for further evaluation of suspected or confirmed residual active acromegaly after primary therapy (TSS alone in 23 patients; TSS with adjunctive fractionated RT in three patients; TSS with adjunctive RT and SRS in one patient; and primary medical therapy in three patients (lanreotide Autogel, n=1; cabergoline, n=1; pegvisomant, n=1)) (Table 1). In all cases of active disease, patients exhibited typical clinical features, with elevated insulin-like growth factor 1 (IGF-1, above the age- and sex-matched reference range), and failure to suppress serum growth hormone (GH) to <0.4 µg/L after a 75 g oral glucose load, and/or GH levels >2.5 µg/L (either random measurement or mean of five samples drawn at 30–to-60-min intervals) (13). Post-treatment imaging had been deemed indeterminate following review by a specialist pituitary multidisciplinary team (MDT) in the referring centre. For patients receiving adjunctive medical therapy at the point of referral, we advised discontinuation of depot somatostatin analogue (SSA) therapy for a minimum of 12 weeks, and dopamine agonist therapy for 4 weeks, before Met-PET/MRI.
<table>
<thead>
<tr>
<th>Case</th>
<th>Age/sex</th>
<th>MRI findings at initial presentation</th>
<th>Previous treatment</th>
<th>GH and IGF-1 levels after previous treatment</th>
<th>MRI findings after previous treatment</th>
<th>Met-PET/MRI findings</th>
<th>Adjunctive therapy</th>
<th>GH and IGF-1 levels after adjunctive therapy</th>
<th>New pituitary deficits after adjunctive therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>34/F</td>
<td>21 mm macro; SSE; right CSE</td>
<td>TSS</td>
<td>0.34 0.77* 0.74</td>
<td>Right sella remnant ± right CSE</td>
<td>No tracer uptake at site of suspected remnant</td>
<td>Not required</td>
<td>– – – –</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>47/M</td>
<td>17 mm macro; minor SSE; SpE</td>
<td>TSS</td>
<td>0.62 1.23* 0.83</td>
<td>Central sella/SpE remnant inferior to normal gland</td>
<td>No tracer uptake at site of suspected remnant</td>
<td>Not required</td>
<td>– – – –</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>25/M</td>
<td>12.5 mm macro; SSE</td>
<td>TSS</td>
<td>&lt;0.05 0.15* 0.97</td>
<td>? left sella remnant</td>
<td>No tracer uptake at site of suspected remnant</td>
<td>Not required</td>
<td>– – – –</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>57/F</td>
<td>11 mm macro; left CSE</td>
<td>TSS</td>
<td>0.20 0.38b 0.70</td>
<td>Left sella remnant</td>
<td>No tracer uptake at site of suspected remnant</td>
<td>Not required</td>
<td>– – – –</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>30/F</td>
<td>22 mm macro; SSE; left CSE; SpE</td>
<td>TSS</td>
<td>10.00 31.2a 3.58</td>
<td>? discrete central sella and left CS remnants</td>
<td>Tracer uptake in suspected sella and CS remnants</td>
<td>Repeat TSS</td>
<td>1.80 2.30a 1.35</td>
<td>LH, FSH, TSH</td>
</tr>
<tr>
<td>6</td>
<td>45/F</td>
<td>19 mm macro; left CSE</td>
<td>TSS</td>
<td>2.00 4.00a 2.75</td>
<td>Small left sella remnant</td>
<td>Tracer uptake in discrete right and left sella remnants</td>
<td>Repeat TSS</td>
<td>0.32 0.45a 0.64</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>53/F</td>
<td>15 mm macro</td>
<td>TSS</td>
<td>1.00 4.20a 2.63</td>
<td>Central sella remnant inferior to normal gland</td>
<td>Tracer uptake in suspected sella remnant</td>
<td>Repeat TSS</td>
<td>0.07 0.60a 0.56</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>58/M</td>
<td>7 mm micro</td>
<td>TSS</td>
<td>0.88 1.50a 2.26</td>
<td>Small left sella remnant</td>
<td>No tracer uptake at site of suspected remnant</td>
<td>Repeat TSS</td>
<td>0.50 0.80a 1.50</td>
<td>ACTH</td>
</tr>
<tr>
<td>9</td>
<td>24/F</td>
<td>26 mm macro; left CSE</td>
<td>TSS</td>
<td>12.6 10.83a 4.29</td>
<td>Central/left sella remnant; ? left CSE</td>
<td>Majority of tracer uptake within sella remnant; small amount of left CS uptake</td>
<td>Repeat TSS</td>
<td>2.70 3.30a 1.68</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>49/F</td>
<td>16 mm macro</td>
<td>TSS</td>
<td>4.19 6.4b 2.07</td>
<td>? discrete right and left sella remnants left sella remnant with probable left CSE</td>
<td>Tracer uptake in both suspected remnants</td>
<td>Repeat TSS</td>
<td>0.58 0.93 0.72</td>
<td>None</td>
</tr>
<tr>
<td>11</td>
<td>36/M</td>
<td>27.5 mm macro; SSE; left CSE</td>
<td>TSS</td>
<td>4.19 NA 3.5</td>
<td>Left sella remnant</td>
<td>Majority of tracer uptake within sella remnant; small amount of left CS uptake</td>
<td>Repeat TSS</td>
<td>2.8 NA 2.18</td>
<td>None</td>
</tr>
<tr>
<td>12</td>
<td>56/M</td>
<td>18.5 mm macro; right CSE</td>
<td>TSS</td>
<td>1.6 NA 1.32</td>
<td>? discrete right (±CSE) and left sella remnants</td>
<td>Tracer uptake in both suspected remnants; no CS uptake</td>
<td>Repeat TSS</td>
<td>&lt;0.05 0.47 0.55</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Case</th>
<th>Age/sex</th>
<th>MRI findings at initial presentation</th>
<th>Previous treatment</th>
<th>GH and IGF-1 levels after previous treatment</th>
<th>MRI findings after previous treatment</th>
<th>Met-PET/MRI findings</th>
<th>Adjunctive therapy</th>
<th>GH and IGF-1 levels after adjunctive therapy</th>
<th>New pituitary deficits after adjunctive therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>52/M</td>
<td>40 mm macro; SSE; left CSE; SpE</td>
<td>TSS</td>
<td>OGTT GH nadir (µg/L) 2.93 GH (µg/L) 3.06&lt;sup&gt;b&lt;/sup&gt; IGF-1 (xULN) 2.69</td>
<td>? sella and sphenoid sinus remnants</td>
<td>Tracer uptake in right sella and part of sphenoid sinus remnant</td>
<td>Repeat TSS</td>
<td>OGTT GH nadir (µg/L) 0.89 GH (µg/L) NA IGF-1 (xULN) 1.53</td>
<td>None</td>
</tr>
<tr>
<td>14</td>
<td>54/M</td>
<td>11 mm macro</td>
<td>TSS</td>
<td>NA GH (µg/L) 1.76&lt;sup&gt;a&lt;/sup&gt; IGF-1 (xULN) 2.35</td>
<td>right sella remnant</td>
<td>Tracer uptake in right sella remnant</td>
<td>Repeat TSS</td>
<td>OGTT GH nadir (µg/L) 0.84 GH (µg/L) 1.30&lt;sup&gt;b&lt;/sup&gt; IGF-1 (xULN) 1.87</td>
<td>None</td>
</tr>
<tr>
<td>15</td>
<td>42/M</td>
<td>17 mm macro</td>
<td>TSSx2</td>
<td>OGTT GH nadir (µg/L) 2.51 GH (µg/L) 2.51&lt;sup&gt;b&lt;/sup&gt; IGF-1 (xULN) 2.24</td>
<td>? right sella remnant; ? right CSE</td>
<td>Tracer uptake in suspected remnant, no CS uptake</td>
<td>Repeat TSS</td>
<td>OGTT GH nadir (µg/L) 1.28 GH (µg/L) 0.71 IGF-1 (xULN) 1.87</td>
<td>None</td>
</tr>
<tr>
<td>16</td>
<td>63/M</td>
<td>27 mm macro; SSE; right CSE</td>
<td>TSSx2; fractionated RT</td>
<td>OGTT GH nadir (µg/L) 3.55 GH (µg/L) 3.08 IGF-1 (xULN) 1.94</td>
<td>right sella remnant; ? right CSE</td>
<td>Tracer uptake only within right sella remnant; no CSE</td>
<td>Repeat TSS</td>
<td>OGTT GH nadir (µg/L) 0.54 GH (µg/L) 1.90 IGF-1 (xULN) 0.79</td>
<td>None</td>
</tr>
<tr>
<td>17</td>
<td>68/F</td>
<td>Enlarged partial empty sella</td>
<td>Pegvisomant 30 mg/day</td>
<td>– OGTT GH nadir (µg/L) 21.5&lt;sup&gt;a&lt;/sup&gt; GH (µg/L) 3.02</td>
<td>Thin rind of tissue lining an enlarged sella</td>
<td>Tracer uptake in suspected sella maximum on left</td>
<td>First TSS</td>
<td>OGTT GH nadir (µg/L) 3.30 GH (µg/L) 3.70&lt;sup&gt;b&lt;/sup&gt; IGF-1 (xULN) 1.88</td>
<td>None</td>
</tr>
<tr>
<td>18</td>
<td>41/M</td>
<td>Enlarged partial empty sella</td>
<td>Cabergoline 3 mg/week</td>
<td>– OGTT GH nadir (µg/L) 1.30&lt;sup&gt;b&lt;/sup&gt; GH (µg/L) 1.40</td>
<td>Thin rind of tissue lining an enlarged sella</td>
<td>Tracer uptake in suspected sella – focal area of maximal uptake on left</td>
<td>First TSS</td>
<td>OGTT GH nadir (µg/L) &lt;0.1 GH (µg/L) &lt;0.1 IGF-1 (xULN) 0.48</td>
<td>None</td>
</tr>
<tr>
<td>19</td>
<td>51/M</td>
<td>Enlarged partial empty sella</td>
<td>ATG 120mg 4-weekly</td>
<td>– OGTT GH nadir (µg/L) 20.50 GH (µg/L) 2.3</td>
<td>Thin rind of tissue lining sella</td>
<td>Tracer uptake throughout sella – maximum on left</td>
<td>Awaiting repeat TSS</td>
<td>OGTT GH nadir (µg/L) NA GH (µg/L) NA IGF-1 (xULN) NA</td>
<td>–</td>
</tr>
<tr>
<td>20</td>
<td>51/F</td>
<td>25 mm macro; SSE</td>
<td>TSS</td>
<td>NA OGTT GH nadir (µg/L) 1.40 GH (µg/L) 4.65&lt;sup&gt;a&lt;/sup&gt; IGF-1 (xULN) 1.63</td>
<td>? right sella remnant; extensive right CSE</td>
<td>Tracer uptake only within right parasellar/CS tumour</td>
<td>Fractionated RT</td>
<td>OGTT GH nadir (µg/L) 0.64&lt;sup&gt;a&lt;/sup&gt; GH (µg/L) 0.46</td>
<td>None</td>
</tr>
<tr>
<td>21</td>
<td>26/F</td>
<td>26 mm macro; SSE; right CSE</td>
<td>TSS</td>
<td>NA OGTT GH nadir (µg/L) 9.7 GH (µg/L) 7.04&lt;sup&gt;a&lt;/sup&gt; IGF-1 (xULN) 3.04</td>
<td>Inferior sella remnant with right CSE</td>
<td>Tracer uptake in right CSE; some sella uptake</td>
<td>Fractionated RT</td>
<td>NA OGTT GH nadir (µg/L) 1.55&lt;sup&gt;b&lt;/sup&gt; GH (µg/L) 0.43</td>
<td>ACTH</td>
</tr>
<tr>
<td>22</td>
<td>41/F</td>
<td>40 mm macro; SSE; right CSE</td>
<td>TSS</td>
<td>NA OGTT GH nadir (µg/L) 1.21 GH (µg/L) 1.30&lt;sup&gt;a&lt;/sup&gt; IGF-1 (xULN) 1.30</td>
<td>? left sella remnant; clear left CS remnant</td>
<td>Tracer uptake in left CSE; some adjacent sella uptake</td>
<td>ATG 90mg 4-weekly</td>
<td>NA OGTT GH nadir (µg/L) 0.59&lt;sup&gt;a&lt;/sup&gt; GH (µg/L) 0.77</td>
<td>–</td>
</tr>
<tr>
<td>23</td>
<td>43/F</td>
<td>28.5 mm macro; left CSE; SpE</td>
<td>TSS</td>
<td>NA OGTT GH nadir (µg/L) 1.9 GH (µg/L) 2.50&lt;sup&gt;b&lt;/sup&gt; IGF-1 (xULN) 1.65</td>
<td>? discrete right and left sella remnants</td>
<td>Tracer uptake in both suspected sella remnants</td>
<td>ATG 120mg 4-weekly</td>
<td>NA OGTT GH nadir (µg/L) NA GH (µg/L) 0.88</td>
<td>–</td>
</tr>
<tr>
<td>24</td>
<td>75/F</td>
<td>Macro&lt;sup&gt;a&lt;/sup&gt;</td>
<td>TSS</td>
<td>NA OGTT GH nadir (µg/L) 1.9 GH (µg/L) 1.15</td>
<td>? left sella remnant; ? CSE</td>
<td>Tracer uptake in left CSE</td>
<td>ATG 120mg 4-weekly</td>
<td>NA OGTT GH nadir (µg/L) 0.50&lt;sup&gt;a&lt;/sup&gt; GH (µg/L) 0.72</td>
<td>–</td>
</tr>
<tr>
<td>25</td>
<td>51/F</td>
<td>18 mm macro; CSE; SpE</td>
<td>TSS</td>
<td>NA OGTT GH nadir (µg/L) 1.9 GH (µg/L) 2.50&lt;sup&gt;b&lt;/sup&gt; IGF-1 (xULN) 1.65</td>
<td>? left sella remnant; ? CSE</td>
<td>Tracer uptake in left CSE</td>
<td>ATG 120mg 4-weekly</td>
<td>NA OGTT GH nadir (µg/L) 0.50&lt;sup&gt;a&lt;/sup&gt; GH (µg/L) 0.72</td>
<td>–</td>
</tr>
</tbody>
</table>
Biochemical measurements

All analytes were measured by a Clinical Pathology Accreditation Limited laboratory (CPA, Middlesex, UK). ATG, lanreotide Autogel; CS, cavernous sinus; CSE, cavernous sinus extension; macro, macroadenoma; micro, microadenoma; NA, not available; OGTT, 75 g oral glucose tolerance test; RT, radiotherapy; SRS, stereotactic radiosurgery; SSE, suprasellar extension; SpE, sphenoid sinus extension; TSS, transsphenoidal surgery.

*Patient scanned while receiving ATG therapy (90 mg four weekly); †denotes mean GH value from 5-point day curve; ‡denotes single random GH level; – denotes measurement not indicated; ‡‡dimensions unknown as presenting MRI unavailable.

<p>| | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>55/M</td>
<td>Macro</td>
<td>TSS; fractionated RT</td>
<td>2.25</td>
<td>2.78</td>
<td>2.49</td>
<td>Thin rim of tissue lining the sella</td>
<td>Tracer uptake in right sella + small focus left of centre</td>
<td>ATG 120 mg 4-weekly</td>
<td>–</td>
</tr>
<tr>
<td>27</td>
<td>60/F</td>
<td>Macro</td>
<td>TSS</td>
<td>NA</td>
<td>1.40</td>
<td>2.19</td>
<td>? right cavernous sinus remnant</td>
<td>Tracer uptake in right CSE and discrete focus in left sella</td>
<td>ATG 120 mg 4-weekly</td>
<td>–</td>
</tr>
<tr>
<td>28</td>
<td>52/M</td>
<td>14.5 mm macro; No SSE; right CSE</td>
<td>TSS</td>
<td>6.6</td>
<td>NA</td>
<td>4.5</td>
<td>? right sella remnant</td>
<td>Tracer uptake in right sella remnant</td>
<td>SRS + ATG 120 mg 4-weekly</td>
<td>–</td>
</tr>
<tr>
<td>29</td>
<td>55/M</td>
<td>15 mm macro; ? left CSE</td>
<td>TSS; fractionated RT</td>
<td>NA</td>
<td>NA</td>
<td>2.6</td>
<td>? left sella remnant</td>
<td>Discrete foci of tracer uptake in mid-sella and left sella regions</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>30</td>
<td>38/F</td>
<td>Macro; SSE</td>
<td>TSS; fractionated RT; SRS</td>
<td>NA</td>
<td>49</td>
<td>1.83</td>
<td>Enlarged, partially empty sella, no discrete residual adenoma</td>
<td>Foci of tracer uptake in posterior right sella</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

ATG, lanreotide Autogel; CS, cavernous sinus; CSE, cavernous sinus extension; macro, macroadenoma; micro, microadenoma; NA, not available; OGTT, 75 g oral glucose tolerance test; RT, radiotherapy; SRS, stereotactic radiosurgery; SSE, suprasellar extension; SpE, sphenoid sinus extension; TSS, transsphenoidal surgery.

All patients were managed in accordance with local and international clinical guidelines (14), and all patients provided informed consent for Met-PET and 3D gradient echo MRI. The decision to offer further treatment was undertaken on a case-by-case basis after discussion by a specialist pituitary MDT comprising pituitary neurosurgeon(s), endocrinologist(s), otolaryngologist(s), radiation oncologist(s), neurosurgeon(s), endocrinologist(s), otolaryngologist(s) and neuroradiologist(s) who had full access to the Met-PET/3D gradient echo MRI scans to aid in decision making. Further surgery or RT was undertaken either at our centre or the referring hospital. The study received institutional approval.

Clinical care

All patients were managed in accordance with local and international clinical guidelines (14), and all patients provided informed consent for Met-PET and 3D gradient echo MRI. The decision to offer further treatment was undertaken on a case-by-case basis after discussion by a specialist pituitary MDT comprising pituitary neurosurgeon(s), endocrinologist(s), otolaryngologist(s), radiation oncologist(s), neurosurgeon(s), endocrinologist(s), otolaryngologist(s) and neuroradiologist(s) who had full access to the Met-PET/3D gradient echo MRI scans to aid in decision making. Further surgery or RT was undertaken either at our centre or the referring hospital. The study received institutional approval.

Pathological examination

Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.

The PET tracer, \( l^-\text{[methyl-11C]}\text{-methionine} \), was synthesised in compliance with good manufacturing practice. Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.

The PET tracer, \( l^-\text{[methyl-11C]}\text{-methionine} \), was synthesised in compliance with good manufacturing practice. Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.

The PET tracer, \( l^-\text{[methyl-11C]}\text{-methionine} \), was synthesised in compliance with good manufacturing practice. Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.

The PET tracer, \( l^-\text{[methyl-11C]}\text{-methionine} \), was synthesised in compliance with good manufacturing practice. Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.

The PET tracer, \( l^-\text{[methyl-11C]}\text{-methionine} \), was synthesised in compliance with good manufacturing practice. Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.

The PET tracer, \( l^-\text{[methyl-11C]}\text{-methionine} \), was synthesised in compliance with good manufacturing practice. Surgical specimens were fixed in 10% neutral buffered formalin and embedded in paraffin. Histopathological confirmation of the presence of a somatotroph tumour was verified by the findings of typical microscopic appearances for a pituitary adenoma with positive immunohistochemical (IHC) staining for GH.
practice using a captive solvent in loop methylation method without preparative HPLC, adapted from methods published previously (15, 16, 17). Briefly, [11C]CO₂ was produced using a PETtrace cyclotron (GE Medical Systems, Milwaukee, WI, USA) via the 14N(p,α)11C reaction before conversion to [11C]MeI in the Mel MicroLab (GE Medical Systems). This was then transferred to the HPLC loop of a modified TRACERlab FXC (GE Medical Systems) synthesiser containing an L-homocysteine precursor solution (0.5 M aqueous NaOH solution in ethanol). 11C-methionine was produced in yields up to 15 GBq with a radiochemical purity of >96% and specific activity between 32.2 and 1564 GBq/µmol (average 205.5 GBq/µmol).

Met-PET imaging

All scans were acquired on a GE Discovery 690 PET-CT scanner (GE Medical Systems). The study was performed 20 min after intravenous administration of 300–400 MBq of L-[methyl-11C]-methionine. A low-dose CT (140 kV, 220 mA, 0.5 s rotation, 0.984 mm pitch) was acquired for attenuation correction followed by a single bed position PET study of the head. Time-of-flight (ToF) PET data were acquired for a total acquisition time of 20 min. PET images were reconstructed with CT attenuation correction using fully 3D iterative reconstruction algorithms (3 iterations, 24 subsets and 2 mm Gaussian post-filter) incorporating ToF and resolution recovery software (VUE Point FX and Sharp IR) to a 3.27 mm slice thickness. The CT images were reconstructed at 1.25 mm slice thickness. Met-PET studies were reviewed by nuclear medicine physicians with expertise in PET-CT on the Xeleris workstation (GE Healthcare).

Standard and 3D gradient echo MRI

Imaging was performed on a 1.5 T superconducting unit (GE Signa, Milwaukee, WI, USA) using a circularly

![Figure 1](#)

*Figure 1*

Case 1 (in remission)

Case 1 (acromegaly in remission after TSS). Post-operative MRI suggests a significant right-sided tumour remnant (white arrows), with normal gland (contrast enhanced, yellow arrow) displaced superiority to the left. However, Met-PET/MRI demonstrates tracer uptake only at the site of the normal gland and confirms no residual functioning tumour at the site of the suspected remnant reported on routine clinical MRI. Met-PET-CT, 11C-methionine PET-CT; Met-PET/MRI, co-registered 11C-methionine PET-CT and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.
polarised head coil. For standard clinical MRI, coronal T1-weighted spin echo images were obtained before and after intravenous injection of 0.1 mmol/kg gadopentetate dimeglumine. Subsequently, a spoiled gradient recalled acquisition (SPGR) sequence was also performed to optimise co-registration with the Met-PET dataset. In brief, sagittal T1-weighted fast spoiled gradient echo images (TR 11.5 ms, TE 4.2 ms, slice thickness 1 mm, 0 mm gap, 256 × 256 matrix) of the whole head were obtained. The absence or presence of cavernous sinus invasion was defined according to Knosp criteria (18). MRI scans were reviewed by neuroradiologists and members of the pituitary MDT both at the local/referring hospitals and in Cambridge.

**Co-registration of Met-PET and MRI**

Met-PET and MRI images were co-registered using ProSoma version 3.3, build 252 software (MedCom GmbH, Darmstadt, Germany). ProSoma is a virtual simulation package used primarily in RT. It allows multiple datasets to be loaded simultaneously and co-registered with each other using a mutual information-based automatic registration algorithm. For the purposes of this work, the SPGR MRI sequence was selected as the primary dataset. The CT dataset acquired as part of the Met-PET imaging was then registered to the MRI and the resulting registration parameters were applied to the PET data to achieve a Met-PET/MRI registration.

**Results**

**Patients with indeterminate MRI appearances but complete remission of acromegaly**

Four patients (cases 1–4) were in complete remission (clinically and biochemically) after primary TSS (Table 1). However, in each of these patients, the post-operative MRI (performed at 3–4 months after surgery) showed suspected residual disease at the site of the original

---

**Figure 2**

Case 2 (acromegaly in remission after TSS). Post-operative MRI suggests a possible tumour remnant (white arrows), inferior to the normal gland (contrast enhanced, yellow arrows). Met-PET/MRI demonstrates tracer uptake only at the site of the normal gland and confirms no residual functioning tumour at the site of the suspected remnant. Met-PET-CT, 11C-methionine PET-CT; Met-PET/MRI, co-registered 11C-methionine PET-CT and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.
tumour. Two neuroradiologists were unable to distinguish between possible residual tumour and post-operative change in each of these patients. In contrast, Met-PET/MRI showed only tracer accumulation corresponding to the normal pituitary gland, with no uptake at sites of suspected residual tumour (Figs 1 and 2).

**Patients with indeterminate MRI appearances and persistent acromegaly**

Twenty-six patients with acromegaly had active disease (cases 5–30) despite previous treatment(s) (Table 1). The majority of patients had undergone single TSS (n=18). Two patients had undergone repeat TSS (cases 15 and 16), one of whom (case 16) had also received post-operative RT. Two patients (cases 26 and 29) had undergone single TSS followed by RT. Another patient (case 30) had undergone TSS, conventional RT and SRS sequentially, with continuing poor control necessitating maximum dose of pegvisomant. Three further patients (cases 17, 18 and 19) had never been offered surgery due to the absence of a clear surgical target on MRI, which showed a large, partially empty sella (Table 1). Several patients were receiving adjunctive medical therapy (depot SSA in 17; cabergoline in one), which was discontinued before Met-PET/MRI (see section: Subjects and methods).

In 25 cases (96%), Met-PET/MRI revealed tracer uptake at sites that were clearly visualised to be separate from the normal pituitary gland (Figs 3, 4, 5, 6, 7 and Table 1). Some, but not all of these sites, had been independently identified as suspicious for residual adenoma on MRI, but with the caveat that the reporting radiologists (and referring pituitary MDTs) were unable to definitively distinguish them from post-treatment changes. In one patient (case 8), Met-PET/MRI did not show any tracer uptake at a site of suspected recurrence (5 mm area adjacent to the left cavernous sinus). However, it transpired that this patient had received a 90 mg depot injection of lanreotide Autogel (ATG) just five weeks before being

**Case 5 (residual active disease)**

![Figure 3](image)

Case 5 (persistent active acromegaly after first TSS). Post-operative MRI suggests a possible sella remnant (white arrows inferior to normal gland (yellow arrows)); Met-PET/MRI reveals tracer uptake (white arrows) in the sella and adjacent to the left internal carotid artery where the greatest intensity is observed (Met-PET axial image, white arrow). Met-PET-CT, $^{11}$C-methionine PET-CT; Met-PET/MRI, co-registered $^{11}$C-methionine PET-CT and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transphenoidal surgery.

www.eje-online.org
scanned, which may have suppressed $^{11}$C-methionine uptake by the tumour.

Based on the Met-PET/MRI findings, 14 patients were referred for first or repeat TSS (Table 1). In all 14 cases, tumour was localised intraoperatively at the sites previously identified as abnormal on Met-PET/MRI, and histological analysis confirmed GH-secreting pituitary adenoma in all but two patients; both of the latter, however, remain in full remission at one- and two-year follow-up respectively, off all treatment (case 7 and case 19). Post-operative endocrine testing (6–12 weeks after TSS and a minimum of 12 weeks after discontinuing medical therapy) showed a marked improvement in disease control in seven patients (with IGF-1 <2.0 × ULN in six subjects) and complete biochemical remission in the other seven cases (Table 1). Reassuringly, only one patient developed new pituitary hormone deficits after Met-PET/MRI-guided surgery (LH, FSH and TSH in subject 5). The only other patient to acquire a new hormone deficit (ACTH) after TSS was case 8 (the single subject with a negative Met-PET/MRI) (Table 1).

One patient underwent SRS (case 28) and achieved biochemical control at one year after treatment; he is now being considered for withdrawal of medical therapy. Two patients (cases 21 and 22), in whom Met-PET/MRI demonstrated clear cavernous sinus invasion, received adjunctive fractionated RT with subsequent normalisation of GH and IGF-1 off all medical therapy by 24 and 48 months respectively. Five patients (cases 23–27) were treated with SSA after rejecting alternative treatment options (Table 1). Three patients are currently awaiting further surgery or SRS.

**Discussion**

In an important subgroup of patients with acromegaly, post-treatment MRI (and/or CT) is unable to reliably

---

**Case 11 (residual active disease)**

![Case 11 (persistent active acromegaly after first TSS). Post-operative MRI shows a thin rind of enhancing tissue lining the floor of the sella (yellow arrow) with a hypointense area adjacent to/extended into the left cavernous sinus (white arrows). Met-PET/MRI reveals tracer uptake predominantly in the left side of the sella adjacent to the cavernous sinus (white arrows), with greatest intensity seen at the posterior aspect (Met-PET axial image, white arrow). Met-PET-CT, $^{11}$C-methionine PET-CT; Met-PET/MRI, co-registered $^{11}$C-methionine PET-CT and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.**

---

**Figure 4**
identify the site(s) of residual/recurrent pituitary adenoma or distinguish suspected adenoma from post-therapy change (e.g. sella remodelling due to scar tissue). In this setting, adjunctive medical therapy (e.g. SSA, dopamine agonist and pegvisomant) or fractionated RT are often preferred because of the lack of a clear target for (repeat) TSS or SRS. Although good disease control can be achieved in the majority of patients with medical therapy and/or conventional RT, they are associated with significant long-term cost (e.g. SSA, pegvisomant) or potential adverse effects (e.g. hypopituitarism after RT). Here, we have shown in the largest cohort of acromegaly patients studied to date that Met-PET/MRI can provide additional data (Figs 3, 4, 5, 6, 7) to help inform management in such cases and may facilitate further targeted treatment with a high probability of achieving a significant improvement in, or complete, disease control. Met-PET/MRI can also exclude suspected residual tumour after successful surgery (Figs 1 and 2).

A potential role for functional imaging with PET in pituitary disease has previously been suggested by several groups (2, 3, 8, 9, 10, 11, 19). Proposed indications include detection of microadenomas in which MRI is either negative or inconclusive (e.g. in up to 40% of Cushing’s disease) (10, 19), discrimination between post-operative changes and residual active adenoma (in non-functioning and functioning tumours) (3, 9, 11) and to evaluate the effects of treatment (e.g. RT, medical therapy) (2, 8, 20). Although FDG-PET has shown utility in some patients, its limited sensitivity (especially for detecting microadenomas) coupled with high background uptake by normal brain have prevented its adoption into routine clinical practice. In contrast, $^{11}$C-methionine shows considerably lower brain uptake (producing a much more favourable target:background ratio), with several studies also reporting increased sensitivity compared with FDG-PET (10, 11). Estimation of tumour metabolism through measurement of the maximum standard(ised) uptake value ($SUV_{max}$), and

**Case 16 (residual active disease)**

<table>
<thead>
<tr>
<th>T1W SE MRI + gadolinium</th>
<th>T1W SE MRI + gadolinium</th>
<th>Met-PET-CT</th>
<th>Met-PET/MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI at presentation</td>
<td>Imaging post-TSSx2 &amp; RT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 5**

Case 16 (persistent active acromegaly despite TSS ×2 and fractionated RT). MRI shows a suspicious area on the right side of the sella with possible cavernous sinus extension (white arrows). Met-PET/MRI confirms tracer uptake in this area without evidence of cavernous sinus invasion. The position of presumed residual normal pituitary tissue is also shown (yellow arrow). Met-PET-CT, $^{11}$C-methionine PET-CT; Met-PET/MRI, co-registered $^{11}$C-methionine PET-CT and MRI; RT, fractionated radiotherapy; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.
comparison with background cerebellar uptake, may help to confirm non-physiological sella uptake (a ratio >2 has been proposed as exceeding that seen in normal pituitary tissue) (2), although ratios <2 may be seen in some tumour subtypes (e.g. corticotroph microadenomas) or when there is low volume residual disease, making this an unreliable means of confirming or refuting the presence of residual functioning tumour (9, 10).

Early PET studies were limited by a lack of spatial resolution, and even modern PET-CT cannot match the anatomical definition offered by MRI (21). In pituitary disease, this presents significant challenges; for example, when trying to locate a small (<5 mm) microadenoma within an otherwise normal gland or determine whether laterally situated tumour is simply abutting or invading (and therefore potentially unresectable) the adjacent cavernous sinus (11). In recognition of this, a small number of studies have been performed in which PET-CT images have been co-registered with contemporaneous fine slice MRI (thereby combining the sensitivity of PET-CT with the anatomical resolution of MRI), with initial reports suggesting significant benefits for tumour localisation (9, 10, 19). If confirmed, these findings provide strong support for future studies using PET-MR.

To date, only a relatively small number of patients with acromegaly have been included in studies of Met-PET, but with generally positive findings. For example, Tang et al. studied four patients with acromegaly in a group of 33 patients with biochemical or radiological evidence of pituitary adenoma recurrence after surgery (3). In 14 of these patients (three of whom had persisting acromegaly), Met-PET detected residual tumour which was not visible on MRI. This information was used to guide SRS in nine patients, including one of those with acromegaly (3). More recently, Rodriguez-Barcelo et al. studied 17 patients with newly diagnosed or surgically treated acromegaly using co-registered PET-CT and MRI. They reported 86% sensitivity and 86% specificity for detecting recurrence after surgery. However, importantly only one patient proceeded to PET-guided treatment (SRS), and no outcome data were provided to confirm the accuracy of the imaging findings (9). Feng et al. comparing FDG-PET and Met-PET in 43 patients with secretory pituitary adenomas, including 16 patients with acromegaly, concluded that although FDG-PET showed high specificity, Met-PET demonstrated greater sensitivity (11). Interestingly, all patients in their cohort had visible tumours on MRI.

Our study significantly extends these earlier findings, reporting the outcomes of Met-PET/MRI in 30 UK patients in whom specialist pituitary MDTs had concluded that post-treatment MRI appearances were indeterminate. We therefore deliberately focused on cases in whom management decisions could benefit from additional information regarding the location of residual tumour (i.e. those who might be considered for further surgery, SRS or focused fractionated RT

Case 17 (residual active disease)

![Figure 6](image.png)

Case 17 (persistent active acromegaly despite maximum dose pegvisomant). MRI shows an enlarged, partially empty sella with no convincing ‘surgical target’. Met-PET reveals foci of increased tracer uptake throughout the sella (white arrows) with maximum left-sided intensity. Met-PET/MRI localises the sites of increased tracer uptake in the pituitary fossa with maximum intensity on the left. Met-PET, $^{11}$C-methionine PET; Met-PET/MRI, co-registered $^{11}$C-methionine PET-CT and MRI; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.
Case 29 (residual active disease)

Case 29 (persistent active acromegaly after first TSS and RT). Post-operative MRI shows a thin rind of poorly enhancing tissue within the floor of the sella (white arrow, coronal (1) image) and a possible second discrete hypointense area adjacent to the left cavernous sinus (white arrow, coronal (2) image). The pituitary stalk is displaced to the right (yellow arrow). Met-PET/MRI reveals tracer uptake at both sites of suspected residual tumour (white arrows), with greatest intensity seen in the tissue lining the floor of the sella centrally (Met-PET axial image, dashed white arrow). Met-PET-CT, $^{11}$C-methionine PET-CT; Met-PET/MRI, co-registered $^{11}$C-methionine PET-CT and MRI; RT, fractionated radiotherapy; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.

Figure 7

Case 29 (persistent active acromegaly after first TSS and RT). Post-operative MRI shows a thin rind of poorly enhancing tissue within the floor of the sella (white arrow, coronal (1) image) and a possible second discrete hypointense area adjacent to the left cavernous sinus (white arrow, coronal (2) image). The pituitary stalk is displaced to the right (yellow arrow). Met-PET/MRI reveals tracer uptake at both sites of suspected residual tumour (white arrows), with greatest intensity seen in the tissue lining the floor of the sella centrally (Met-PET axial image, dashed white arrow). Met-PET-CT, $^{11}$C-methionine PET-CT; Met-PET/MRI, co-registered $^{11}$C-methionine PET-CT and MRI; RT, fractionated radiotherapy; SE, spin echo; SPGR, spoiled gradient recalled; T1W, T1 weighted; TSS, transsphenoidal surgery.

(i.e. confined to site of suspected tumour remnant only)). We have also provided detailed surgical, pathological and post-operative data for each case, thus correlating Met-PET/MRI findings with key clinical outcomes.

Importantly, in four patients with suspected residual tumour on post-operative MRI, but no clinical or biochemical evidence of active disease, Met-PET/MRI demonstrated no abnormal tracer uptake (Figs 1 and 2). Such findings may explain the apparent discrepancies noted by other workers in post-surgical acromegaly (22). In contrast, in 25 of 26 patients with persistent disease after primary therapy, Met-PET/MRI identified one or more foci of abnormal tracer uptake either confirming suspicious areas seen on MRI or revealing previously unsuspected sites of residual disease (Figs 3, 4, 5, 6, 7 and Table 1). In all 25 patients, the findings of Met-PET/MRI were used for decision making by a specialist pituitary MDT with respect to adjunctive therapy. In 15 patients, repeat ($n=12$) or first ($n=3$) TSS were advised, and in the 14 patients operated to date, all had intraoperative confirmation of residual tumour at the sites suspected on Met-PET/MRI. Although two patients had negative histology, both remain in remission after TSS. All patients experienced a significant improvement in disease control, with six achieving IGF-1 $<2.0 \times \text{ULN}$ and seven full biochemical remission.
Interestingly, in the three patients considered to have a predominantly empty sella on initial MRI, such that surgery was not considered advisable, Met-PET/MRI identified clear foci of microscopic disease (subsequently confirmed at surgery to be adherent to a thin layer of residual normal pituitary tissue) (Fig. 6). Two of these patients were able to discontinue medical therapy completely after surgery, whereas the third had an 85% reduction in GH levels. For other patients, Met-PET/MRI confirmed the suspicion of significant parasellar disease and led to recommendations to continue adjunctive medical therapy or consider fractionated RT or SRS (Table 1). In one patient (case 30), Met-PET/MRI offered an explanation for the failure of previous SRS to achieve complete disease control, identifying foci of residual functioning adenoma that were outside the SRS treatment field (Fig. 7).

We believe that our findings therefore provide additional evidence to support a role for Met-PET/MRI in selected cases of acromegaly where there is evidence of residual disease activity after primary therapy, but in whom post-treatment MRI is inconclusive. Specifically, we have identified three potential indications:

i. To distinguish between residual functioning tumour and post-treatment remodelling;
ii. To delineate sites of residual adenoma that are potentially amenable to (further) surgery or targeted RT in patients with persistent disease after primary therapy, but indeterminate MRI findings;
iii. To confirm sites of residual functioning tumour after failed RT or SRS.

Met-PET/MRI has one major drawback – due to the short half-life of 11C-methionine (~20 min), scanning can only be performed in PET centres with an adjacent cyclotron. This inevitably means that some patients will need to travel significant distances to be imaged. However, it can be argued that concentrating expertise in only a small number of centres is also potentially desirable, especially for a technique that is only likely to find use in a subgroup of patients. In addition, our observations in case 8 are consistent with previous reports that medical treatment, which specifically suppresses hormone synthesis may result in a false-negative scan. Accordingly, we would agree with previous recommendations to discontinue depot SSA therapy 12 weeks, and dopamine agonist therapy 4 weeks, before functional imaging with 11C-methionine PET.

Conclusions

Met-PET/MRI represents an important opportunity for personalising management (23) in selected patients with acromegaly. We have shown that accurate localisation of residual tumour can facilitate targeted therapy to increase the rate of clinical and biochemical remission, while preserving normal pituitary function, and potentially sparing expensive long-term medical treatment or the adverse effects of RT.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements

The authors thank clinicians who have referred patients to our centre for further investigation. The authors also thank the WBC Radiopharmaceutical Unit team. O K, A S P, N B, J D P and M G are supported by the NIHR Cambridge Biomedical Research Centre. J D P has received support by an NIHR Senior Investigator award and NIHR brain injury HTC.

References

7. Sattler MG, Vroomen PC, Slutter WJ, Schers HJ, van den Berg G, Langendijk JA, Wolfenbuttel BH, van den Bergh AC & van Beek AP. Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative...


